merislon eisai tokyo japan 相關
廣告
搜尋結果
2024年3月29日 · TOKYO, Mar 29, 2024 - (JCN Newswire) - - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant MyonalJapan
Login Page - Eisai Sensei
For detailed information about the use of Merislon in children, pregnancy and breastfeeding, and for questions about drug interactions, please check with your pharmacist or doctor. Disclaimer: our goal is to provide you with the most relevant drug information and common dosage for Hong Kong.
2024年5月15日 · October 13, 2023. Eisai Inc.'s U.S. Headquarters Earns Three Key Building Certifications Efforts Aimed to Help Sustain the Environment, Boost Employee Health & Wellness. March 9, 2023. Warning Against Solicitation, Fraudulent Emails, etc. that Use the Name of Eisai or Related Parties. February 17, 2023.
2024年3月29日 · TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Jap…
2024年3月29日 · Merislon and Myonal have been widely used by patients in Japan for a long time since their launch in 1969 and 1983, respectively. Eisai has determined that divesting rights for these products to Kaken, which has strengths in the products’
2022年11月7日 · Eisai will retain its manufacturing rights to and continue to distribute the products in countries such as Japan, China and South Korea. DKSH is a leading provider of "Market Expansion Services" that comprehensively supports companies' business growth and entry into new markets, especially in Asia, and is already responsible for supplying Eisai's products in some parts of Asia.
